Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | FNTA | P49354 | 6/20 | 0.49 |
| ▸ | FNTB | P49356 | 6/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373792 | 1.00 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL8460496 | 1.00 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL4349316 | 1.00 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL7551020 | 1.00 | TACR1 (1.00) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729727 | 0.90 | TACR1 (0.82) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL21286546 | 0.90 | TACR1 (0.81) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729596 | 0.89 | TACR1 (0.80) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729430 | 0.89 | TACR1 (0.80) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9731121 | 0.84 | TACR1 (0.73) | TACR1MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9729517 | 0.83 | TACR1 (0.71) | TACR1MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-01-21 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| EP-1496059-B1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | KIT, TACR1, MRGPRX2 | TACR1 2/4885MEN1 4078/4885KMT2A 2318/4885 |
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OPRK1, OPRL1, KLKB1 | TACR1 18/4885MEN1 3315/4885KMT2A 1696/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | TACR1 119/4885MEN1 4823/4885KMT2A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.